Research programme: HDAC6 inhibitors - Convalife
Alternative Names: CVL-608; CVL-608 series compoundsLatest Information Update: 28 Jul 2024
At a glance
- Originator Convalife
- Class Antineoplastics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in China
- 28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in China
- 22 Jun 2020 Preclinical trials in Haematological malignancies in China (unspecified route) before June 2020